10-K Filing

Xenetic Biosciences, Inc. CIK: 1534525 FY 2021

Filing Information

Form Type	10-K
Accession Number	`0001683168-22-001839`
Period End Date	20211231
Filing Date	20220322
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	xenetic_i10k-123121_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 48 Income Statement 30 Cash Flow Statement 46 Stockholders Equity 18

Balance Sheet 48 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$11.53M	USD	Point-in-time
Cash	`Cash`	$18.24M	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$841.96K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$479.40K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$18.72M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.37M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.09M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$809.99K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Total assets	`Assets`	$19.82M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	8.77M	shares	Point-in-time
Total assets	`Assets`	$13.18M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.47M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	8.75M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.44M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$362.47K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$327.40K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$1.06M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$609.53K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$936.93K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.42M	USD	Point-in-time
Other long-term liabilities	`DeferredIncomeTaxLiabilitiesNet`	$27.04K	USD	Point-in-time
Other long-term liabilities	`DeferredIncomeTaxLiabilitiesNet`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$1.42M	USD	Point-in-time
Total liabilities	`Liabilities`	$963.97K	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 50,000,000 shares authorized as of December 31, 2021 and December 31, 2020; 13,466,603 and 8,772,198 shares issued as of December 31, 2021 and December 31, 2020, respectively; 13,439,612 and 8,745,207 shares outstanding as of December 31, 2021 and December 31, 2020, respectively	`CommonStockValue`	$13.46K	USD	Point-in-time
Common stock, $0.001 par value; 50,000,000 shares authorized as of December 31, 2021 and December 31, 2020; 13,466,603 and 8,772,198 shares issued as of December 31, 2021 and December 31, 2020, respectively; 13,439,612 and 8,745,207 shares outstanding as of December 31, 2021 and December 31, 2020, respectively	`CommonStockValue`	$8.77K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$194.13M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$205.95M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-182.55M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-176.90M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$17.21M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$18.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$12.22M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$13.18M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$19.82M	USD	Point-in-time

Income Statement 30 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`Revenues`	$1.16M	USD	Annual
Total revenues	`Revenues`	$436.94K	USD	Annual
Total revenue	`Revenues`	$1.16M	USD	Annual
Total revenue	`Revenues`	$436.94K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.73M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.16M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.40M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.74M	USD	Annual
Asset impairment charges (Note 6)	`AssetImpairmentCharges`	-	USD	Annual
Asset impairment charges (Note 6)	`AssetImpairmentCharges`	$9.24M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$14.37M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$6.91M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-5.75M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-13.94M	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$-492.00	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$1.12K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$100.47K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$126.17K	USD	Annual
Total other income, net	`NonoperatingIncomeExpense`	$101.59K	USD	Annual
Total other income, net	`NonoperatingIncomeExpense`	$125.68K	USD	Annual
Loss before income taxes	`ProfitLoss`	$-13.81M	USD	Annual
Loss before income taxes	`ProfitLoss`	$-5.65M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-2.92M	USD	Annual
Net loss	`NetIncomeLoss`	$-10.89M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.65M	USD	Annual
Basic and diluted net loss per share	`EarningsPerShareBasicAndDiluted`	$-0.55	USD	Annual
Basic and diluted net loss per share	`EarningsPerShareBasicAndDiluted`	$-1.70	USD	Annual
Weighted-average shares of common stock outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.39M	shares	Annual
Weighted-average shares of common stock outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	10.28M	shares	Annual

Cash Flow Statement 46 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-10.89M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.65M	USD	Annual
Asset impairment charges	`OtherAssetImpairmentCharges`	-	USD	Annual
Asset impairment charges	`OtherAssetImpairmentCharges`	$9.24M	USD	Annual
Deferred income taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	-	USD	Annual
Deferred income taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$2.92M	USD	Annual
Depreciation	`Depreciation`	$757.00	USD	Annual
Depreciation	`Depreciation`	-	USD	Annual
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$35.48K	USD	Annual
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$28.08K	USD	Annual
Gain on settlement with vendor	`GainsLossesOnExtinguishmentOfDebt`	$143.64K	USD	Annual
Gain on settlement with vendor	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Share-based expense	`ShareBasedCompensation`	$410.44K	USD	Annual
Share-based expense	`ShareBasedCompensation`	$468.91K	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-325.66K	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-4.06K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$457.13K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-378.11K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.27M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.74M	USD	Annual
Net proceeds from issuance of common stock and warrants	`ProceedsFromOtherEquity`	$11.45M	USD	Annual
Net proceeds from issuance of common stock and warrants	`ProceedsFromOtherEquity`	-	USD	Annual
Net proceeds from issuance of common stock	`ProceedsFromIssuanceOrSaleOfEquity2`	-	USD	Annual
Net proceeds from issuance of common stock	`ProceedsFromIssuanceOrSaleOfEquity2`	$5.43M	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$3.68K	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.45M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.43M	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$1.16M	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$6.72M	USD	Annual
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.37M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.37M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Right of use asset obtained in exchange for lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$70.56K	USD	Annual
Right of use asset obtained in exchange for lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	-	USD	Annual
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	$1.00	USD	Annual
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	$7.00	USD	Annual
Issuance of common stock in connection with warrant buyout	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	-	USD	Annual
Issuance of common stock in connection with warrant buyout	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	$41.07K	USD	Annual
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$6.00	USD	Annual
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$229.00	USD	Annual

Stockholders Equity 18 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$17.21M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time
Issuance of common stock and warrants, net of issuance costs	`IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts`	$11.45M	USD	Annual
Exercise of pre-funded warrants	`ExerciseOfPrefundedWarrantsValue`	$3.68K	USD	Annual
Issuance of common stock in registered direct offering, net of issuance costs	`StockIssuedDuringPeriodValueNewIssues`	$5.43M	USD	Annual
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	Annual
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	Annual
Issuance of common stock to vendor	`StockIssuedDuringPeriodValueOther`	-	USD	Annual
Issuance of common stock to vendor	`StockIssuedDuringPeriodValueOther`	-	USD	Annual
Issuance of common stock in connection with warrant buyout	`IssuanceOfCommonStockInConnectionWithWarrantBuyout`	$-41.07K	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$410.44K	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$468.91K	USD	Annual
Net loss	`NetIncomeLoss`	$-10.89M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.65M	USD	Annual
Ending balance, value	`StockholdersEquity`	$17.21M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.